Avapritinib rollover trial aims to confirm Long-Term safety for mastocytosis patients
NCT ID NCT06748001
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at the long-term safety of the drug avapritinib (AYVAKIT®) in people with systemic mastocytosis who have already been taking it and benefiting from it in a previous study. About 60 participants will continue receiving the drug and be monitored for serious side effects. The goal is to see if avapritinib remains safe over time for controlling this rare disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avapritinib (AYVAKIT®)
What this could lead to
If successful, this study could confirm that avapritinib is safe for long-term use in controlling systemic mastocytosis, supporting its continued use as a maintenance therapy.
What could go wrong
This is a small, open-label rollover study with no placebo group, so results may not prove long-term safety definitively. Side effects like swelling, nausea, or cognitive changes remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASTOCYTOSIS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno
RECRUITINGSalerno, 84131, Italy
-
Erasmus Medisch Centrum
RECRUITINGRotterdam, 3015, Netherlands
-
Guys and St Thomas NHS Foundation Trust - St Thomas Hospital
RECRUITINGLondon, SE19RT, United Kingdom
-
Oslo University Hospital
RECRUITINGOslo, 0424, Norway
-
The Hospital for Sick Children
RECRUITINGToronto, Ontario, M5G 1X8, Canada
-
Universitair Medisch Centrum Groningen
RECRUITINGGroningen, 9700, Netherlands
-
Universitair Ziekenhuis Antwerpen (UZA)
RECRUITINGEdegem, 2650, Belgium